Dementia with Lewy bodies by McKeith, Ian
ementia with Lewy bodies (DLB) is probably
the second most prevalent cause of degenerative demen-
tia in older people; only Alzheimer’s disease (AD) is
more common.For example,a recent community study
of 85+ year olds found 5.0% to meet clinical diagnostic
criteria for DLB, representing 22% of all demented
cases.
1 Despite its high prevalence,DLB was only fully
recognized about a decade ago,as a result of improved
methods of neuropathological staining,which allowed the
key lesions (Lewy bodies [LBs]) to be seen in autopsy
brain tissue.
2 It is therefore a relative newcomer for many
clinicians,for whom it poses significant difficulty in ante-
mortem diagnosis.The importance of recognizing DLB
relates particularly to its pharmacological management,
with reports of good responsiveness to cholinesterase
inhibitors,
3 but extreme sensitivity to the side effects of
neuroleptics.
4,5This article,which reviews current knowl-
edge and opinion about DLB,is based upon the deliber-
ations of two recent international consensus meetings.
6,7
Diagnostic concepts
DLB has carried a variety of diagnostic labels during the
last two decades, including diffuse Lewy body disease
(DLBD),
8 Lewy body dementia (LBD),
9 the Lewy body
variant of Alzheimer’s disease (LBVAD),
10 senile demen-
tia of Lewy body type (SDLT),
11 and dementia associated
with cortical Lewy bodies (DCLB).
12This multiplicity of
terms reflects the coexistence in the brains of these cases
of α-synuclein–positive LBs and Lewy neurites (LNs) and
abundant Alzheimer-type pathology,predominantly in the
form of amyloid plaques.Tau-positive inclusions and neo-
cortical neurofibrillary tangles sufficient to meet Braak
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Dementia with Lewy bodies (DLB) is the second most com-
mon cause of neurodegenerative dementia in older peo-
ple, accounting for 10% to 15% of all cases. It occupies
part of a spectrum that includes Parkinson’s disease and
primary autonomic failure. All these diseases share a neu-
ritic pathology based upon abnormal aggregation of the
synaptic protein  -synuclein. It is important to identify DLB
patients accurately because they have specific symptoms,
impairments, and functional disabilities that differ from
other common dementia syndromes such as Alzheimer’s
disease, vascular cognitive impairment, and frontotem-
poral dementia. Clinical diagnostic criteria for DLB have
been validated against autopsy, but fail to detect a sub-
stantial minority of cases with atypical presentations that
are often due to the presence of mixed pathology. DLB
patients frequently have severe neuroleptic sensitivity
reactions, which are associated with significantly increased
morbidity and mortality. Cholinesterase inhibitor treat-
ment is usually well tolerated and substantially improves
cognitive and neuropsychiatric symptoms. Although vir-
tually unrecognized 20 years ago, DLB could within this
decade become one of the most treatable neurodegen-
erative disorders of late life.  
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:333-341.stages V or VI occur in only a minority of cases (Figure 1).
Alzheimer pathology is not a prerequisite for the exis-
tence of dementia however,since cases with “pure”LB
disease may present clinically with cognitive impairment
and other neuropsychiatric features.Nor is the number
of cortical LBs robustly correlated with either the sever-
ity or the duration of dementia,
13,14 although associations
have been reported with LB and plaque density in mid-
frontal cortex.
15 LN and neurotransmitter deficits are sug-
gested as more likely correlates of clinical symptoms.
14,16
α-Synuclein immunoreactive deposits with many of the
characteristics of LBs have also been reported in a high
proportion of AD cases,particularly in the amygdala.
17 In
this context,they may represent an end-stage phenome-
non,with secondary accumulation of aggregated synu-
clein in severely dysfunctional neurones that are already
heavily burdened by plaque and tangle pathology.
18
Whatever the explanations are for this considerable over-
lap in pathological lesions in DLB and AD,it is clear that
clinical separation of cases is going to be less than 100%
precise.The presence of Alzheimer pathology in DLB
appears to modify the typical clinical presentation mak-
ing such cases harder to differentiate clinically,
19 with the
core features (see below) being scant or absent and the
clinical picture more closely resembling AD.
DLB and Parkinson’s disease dementia 
The clinical and pathological classification of DLB is fur-
ther complicated by its relationship with idiopathic
Parkinson’s disease,a disorder in which dementia may
develop in up to 78% patients
20 and which is similar to
DLB
21,22 in respect of fluctuating neuropsychological
function,
23 neuropsychiatric features,
24 and extrapyrami-
dal motor features (Table I).
25
There is considerable debate as to the relationship
between the two diagnoses.
26An arbitrary “1-year rule”is
frequently used to “separate” them by proposing that
onset of dementia within 12 months of parkinsonism qual-
ifies as DLB and more than 12 months of parkinsonism
before dementia qualifies as Parkinson’s disease demen-
tia (PDD).This is certainly helpful in individual clinical
case diagnosis and management,but is increasingly hard
to justify from a neurobiological point of view.There do
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Figure 1. The neuropathology of dementia with Lewy bodies (DLB). LBs,
Lewy bodies; AD, Alzheimer’s disease.
Cortical and
 subcortical LBs
Neocortical
neurofibrillary
      tangles
infrequent
β-Amyloid
plaques
 similar to AD
Table I. Similarities between dementia with Lewy bodies (DLB) and
Parkinson’s disease dementia (PDD).
Cognitive profile
Fluctuating cognition
Extrapyramidal features
Neuropsychiatric symptoms
Lewy body distribution and density
Cholinergic and dopaminergic deficits
Neuroleptic sensitivity
Response to cholinesterase inhibitorsnot seem to be major neuropathological differences
between DLB and PDD,and it is not possible to make a
confident retrospective clinical diagnosis based on autopsy
findings alone.A Task Force of the Movement Disorders
Society is presently addressing the issues of PD dementia,
and its recommendations should help to clarify this com-
plex and currently problematic area.
Clinical criteria for DLB
The core clinical features of DLB,as defined by consensus
criteria (Table II),
27 are fluctuating cognitive impairment,
recurrent visual hallucinations, and parkinsonism. The
specificity of a clinical diagnosis of “probable DLB”(two
or more core features present) is high at >80%,but sensi-
tivity is generally limited to around 50%.
28The use of the
more lenient “possible DLB”criteria,which require the
presence of only one core feature,increases case detection
rates at the cost of reduced diagnostic accuracy and may
be useful in clinical practice for screening purposes.
29
Clinical presentation and course of DLB
In general terms,the onset of DLB tends to be insidious,
although reports of a period of increased confusion,the
onset of hallucinations,or a significant fall may give the
impression of a sudden onset.The main differential diag-
noses of DLB are AD,vascular dementia,PDD,atypical
parkinsonian syndromes,such as progressive supranu-
clear palsy (PSP),multiple system atrophy (MSA),and
corticobasal degeneration (CBD),and also Creutzfeld-
Jakob disease (CJD).
27The course of DLB is progressive,
with cognitive test scores declining about 10% per
annum,similar to AD.
30 Cognitive fluctuations may con-
tribute to large variability in repeated test scores,eg,five
Mini-Mental State Examination (MMSE) points differ-
ence over the course of a few days or weeks,
31 making it
difficult to be sure of the severity of cognitive impair-
ment by single examination.Survival times from onset
until death are similar to AD,
32 although a minority of
DLB patients have a very rapid disease course.
33,34
The clinical diagnosis of DLB rests on obtaining a
detailed history of symptoms from the patient and an
informant,mental state examination,appropriate cogni-
tive testing,and neurological examination.Systemic and
pharmacological causes of delirium need to be excluded.
There are as yet no clinically applicable electrophysio-
logical,genotypic,or cerebrospinal fluid (CSF) markers
to support a DLB diagnosis,
7 but neuroimaging investi-
gations may be helpful in supporting the clinical diagno-
sis.Changes associated with DLB include preservation
of hippocampal and medial temporal lobe volume on
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Table II. Consensus guidelines for the clinical diagnosis of probable and possible dementia with Lewy bodies (DLB).
27
Central feature
• Progressive cognitive decline of sufficient magnitude to interfere with normal social and occupational function. Prominent or
persistent memory impairment may not necessarily occur in the early stages, but is usually evident with progression. Deficits
on tests of attention and of frontal-subcortical skills and visuospatial ability may be especially prominent
Core features (two core features essential for a diagnosis of probable DLB, one for possible DLB)
• Fluctuating cognition with pronounced variations in attention and alertness
• Recurrent visual hallucinations that are typically well formed and detailed
• Spontaneous features of parkinsonism
Supportive features
• Repeated falls
• Syncope
• Transient loss of consciousness
• Neuroleptic sensitivity
• Systematized delusions
• Hallucinations in other modalities
• Rapid-eye movement (REM) sleep behavior disorder
• Depression
Features less likely to be present
• History of stroke
• Any other physical illness or brain disorder sufficient enough to interfere with cognitive performancemagnetic resonance imaging (MRI)
35,36 and occipital
hypoperfusion on single-photon emission computed
tomography (SPECT).
37,38 Other features,such as gener-
alized atrophy,
36 white matter changes,
39 and rates of pro-
gression of whole brain atrophy,
40 appear to be unhelpful
in differential diagnosis.Dopamine transporter loss in the
caudate and putamen,a marker of nigrostriatal degen-
eration can be detected by dopaminergic SPECT and,in
preliminary studies,has shown specificity and sensitivity
of 85% or higher,and may be particularly helpful.
41,42
Fluctuating cognition
The profile of neuropsychological impairments in patients
with DLB differs from that of AD and other dementia
syndromes,
43 reflecting the combined involvement of cor-
tical and subcortical pathways and relative sparing of the
hippocampus.Patients with DLB perform better than AD
on tests of verbal memory,
44 but worse on visuospatial per-
formance tasks
45 and tests of attention.
46 Fluctuations in
cognitive function,which may vary over minutes,hours,
or days,occur in 50% to 75% of patients,and are associ-
ated with shifting levels of attention and alertness.The
assessment of fluctuating cognitive impairment poses con-
siderable difficulty to most clinicians and has been repeat-
edly cited as a reason for low clinical ascertainment of
DLB.
31,47 Newly proposed methods of assessment may be
particularly helpful in this regard.These include caregiver-
and observer-rated scales.
48 Questions such as whether
there are episodes when the patient’s thinking seems
quite clear and then becomes muddled may be useful
probes,
49,50 although one recent study
51 found carers’
reports of fluctuation to be less reliable predictors of DLB
diagnosis than more objective questions about daytime
sleepiness, episodes of staring blankly, or incoherent
speech (Table III).Recording variation in attentional per-
formance using a computer-based test system
52 offers an
independent method of measuring fluctuation,which is
also sensitive to drug treatment effects.
53
Neuropsychiatric features
Although the expression “noncognitive features of
dementia”is frequently used to describe a multiplicity of
symptoms such as apathy,anxiety,delusions,hallucina-
tions,and depression that are common in dementia,this
term implies,probably incorrectly,that such features are
independent of cognitive dysfunction.“Neuropsychiatric
features”
54 is a more useful epithet to describe such symp-
toms,which are particularly common in DLB and which
often prompt referral for clinical assessment.
Visual hallucinations are the most characteristic neu-
ropsychiatric feature of DLB,and it is their persistence
55
that helps distinguish them from the episodic perceptual
disturbances that occur transiently in dementias of other
etiology or during a delirium provoked by an external
cause.They are present in 33% of DLB cases at the time
of presentation (range 11%-64%) and occur at some point
during the course of the illness in 46% (13%-80%).
56Well-
formed, detailed, and animate figures are experienced,
provoking emotional responses varying through fear,
amusement,or indifference,usually with some insight into
the unreality of the episode once it is over.It has been sug-
gested that repeated visual hallucinations and associated
visual phenomena in DLB are underpinned by distur-
bances in a lateral frontal cortex–ventral visual stream sys-
tem,
57 emphasizing the cognitive basis of such symptoms.
Visual hallucinations in DLB are associated with greater
deficits in cortical acetylcholine
58 and predict better
response to cholinesterase inhibitors.
59
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Table III. Assessing cognitive fluctuation in dementia with Lewy bodies (DLB). AD, Alzheimer’s disease.
Ferman et al
51 Bradshaw et al
50
• Most carers report fluctuations • Most carers report fluctuations
• DLB patients 87%; AD patients 73%  • DLB patients 77%; AD patients 67%
Four items distinguish DLB and AD Qualitative differences distinguish between fluctuations
• Daytime drowsiness and lethargy in DLB and AD
• Daytime sleep >2 h
• Staring into space for long periods Examples of “worst and best period of function” 
• Episodes of disorganized speech discriminated DLB patients 89% correct; 
AD patients 4% correct
3 or 4 features in 63% DLB patients, 12% AD patients, 
and 0.5% controlsMotor parkinsonism
Extrapyramidal signs (EPS) are reported in 25% to 50%
of DLB cases at diagnosis,and 75% to 80% of patients
develop some EPS during the natural course.The profile
of EPS in DLB is generally similar to that in age-
matched nondemented PD patients
25 with greater pos-
tural instability and facial impassivity,but less tremor.
60
Rate of motor deterioration is about 10% per annum,
similar to PD,
61 but levodopa responsiveness is reduced,
possibly due to additional intrinsic striatal pathology and
dysfunction.
62
Supportive features
Repeated falls,syncope,and transient losses of 
consciousness
Dementia of any etiology is probably a risk factor for all
three of these clinical features and it can be difficult to
clearly distinguish between them.Repeated falls may be
due to posture,gait,and balance difficulties,particularly
in patients with parkinsonism. Reported fall rates are
28% at the time of presentation (range 10%-38%) and
37% (22%-50%) at some point during the illness.
56
Syncopal attacks in DLB with complete loss of con-
sciousness and muscle tone may represent the extension
of LB-associated pathology to involve the brain stem and
autonomic nervous system, leading to orthostatic
hypotension and/or carotid sinus hypersensitivity,which
are more common in DLB than AD or age-matched con-
trols.
63The associated phenomenon of transient episodes
of unresponsiveness without loss of muscle tone may rep-
resent one extreme of fluctuating attention and cognition.
Neuroleptic sensitivity
The hypothesis,first made by the Newcastle group,of an
abnormal sensitivity to adverse effects of neuroleptic
medication was based upon two sets of independent
observations. In the first, 67% (14/21) DLB patients
received neuroleptics and 57% (8/14) deteriorated
rapidly after either receiving them for the first time,or
following a dose increase.
44 Mean survival time for these
8 patients was reduced to 7.4 months,significantly less
than for the 6 patients who had only mild to no adverse
reaction (28.5 months) and the 7 never receiving neu-
roleptics (17.8 months).In the second study,54% (7/16)
neuroleptic-treated DLB patients had neuroleptic sensi-
tivity reactions and their mortality risk,estimated by sur-
vival analysis, was increased by a factor of 2.7.
4 Newer
atypical antipsychotics used at low dose may be safer in
this regard, but sensitivity reactions have been docu-
mented with most and they should be used with great
caution.
7
Other clinical features
Delusions are common in DLB, in 56% at the time of
presentation and 65% at some point during the illness.
They are usually based on recollections of hallucinations
and perceptual disturbances and consequently often have
a fixed,complex,and bizarre content that contrasts with
the mundane and often poorly formed persecutory ideas
encountered in AD patients,which are based on forget-
fulness and confabulation.
Auditory hallucinations occur in 19% (range 13%-30%)
at presentation and 19% (13%-45%) at any point.
Together with olfactory and tactile hallucinations,these
may be important features in some DLB cases and can
lead to initial diagnoses of late-onset psychosis
64 and tem-
poral lobe epilepsy.
44
Sleep disorders have more recently been recognized as
common in DLB with daytime somnolence and nocturnal
restlessness,
65 sometimes as prodromal features.Rapid-eye
movement (REM) sleep-wakefulness dissociations may
explain several features of DLB that are characteristic of
narcolepsy (REM sleep behavior disorder,daytime hyper-
somnolence,visual hallucinations,and cataplexy).
66 Sleep
disorders may contribute to the fluctuations typical of
DLB and their treatment may improve fluctuations and
quality of life.
66 Early urinary incontinence has been
reported in DLB compared with AD,
67 reflecting involve-
ment of autonomic systems. Depressive symptoms are
reported in 33% to 50% of DLB cases,a rate higher than
in AD and similar to PD,
68 and may be related to involve-
ment of monoaminergic brain-stem nuclei.
Management of DLB
General considerations
When dealing with the management of DLB or PDD
patient,it is helpful first to draw up a problem list of cog-
nitive,psychiatric,and motor disabilities,and to then ask
the patient and carer to identify the symptoms that they
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est priority for treatment.
69The clinician should explain,
before any drugs are prescribed,that treatment gains in
target symptoms may be associated with worsening of
symptoms in other domains.The specific risks of neu-
roleptic sensitivity reactions (see above) should be men-
tioned in all cases and it is prudent to mark patient case
notes and records with an alert to reduce possibility of
inadvertent neuroleptic prescribing,particularly in pri-
mary care or emergency room settings.
Nonpharmacological strategies for cognitive symptoms,
including explanation,education,reassurance,orienta-
tion and memory prompts,attentional cues,and targeted
behavioral interventions,are an integral part of the man-
agement of DLB,and pharmacological treatment is most
successful when prescribed as part of a comprehensive
management approach.Similarly,if a patient with DLB
has become acutely confused and psychotic,intercurrent
infection and subdural hematoma,in particular,should
be actively excluded.It cannot always be assumed that
worsening of symptoms is simply part of the natural fluc-
tuating history of DLB.
Specific treatments
The effectiveness of levodopa on motor symptoms in
DLB is thought to be less than in uncomplicated PD,
though trial data are lacking.Treatment refractoriness
may be related to intrinsic striatal degeneration in DLB
and PDD.
70The clinician should aim for the lowest effec-
tive dose of levodopa monotherapy,
71 since higher doses
or other antiparkinsonian agents,are likely to be asso-
ciated with increased confusion and hallucinations.
Evidence is accumulating that cholinesterase inhibitor
(ChEI) drugs are effective and relatively safe in the treat-
ment of neuropsychiatric and cognitive symptoms in
DLB and PDD,but the number of patients studied is rel-
atively small and larger trials are still needed.In addition
to the usual gastrointestinal side effects associated with
this class of drug,increased cholinergic activity in DLB
patients may cause hypersalivation, rhinorrhea, and
lacrimation,
72 and exacerbate postural hypotension and
falls.
73 Improvements are generally reported as greater
than those achieved in AD (Figure 2).
74,75
Apathy,anxiety,impaired attention,hallucinations,delu-
sions, sleep disturbance, and cognitive changes are the
most frequently cited treatment-responsive symptoms in
DLB patients treated with ChEIs.
3,76,77
These responses are consistent with the loss of basal fore-
brain and pedunculopontine cholinergic projection neu-
rones and the associated neocortical cholinergic deficits
58
that have been identified in DLB.Reduction in tempo-
ral choline acetyltransferase (ChAT) is more extensive
in those DLB patients with hallucinations than in those
without,
78 and increased muscarinic receptor density,
which probably occurs in response to the marked presy-
naptic cholinergic deficits,is particularly pronounced in
DLB patients with delusions compared with those with-
out.
79 DLB patients with visual hallucinations were
recently reported to experience greater improvements in
performance of attentional tasks following ChEI admin-
istration compared with nonhallucinators.
59 There are
only limited open-label data available of long-term treat-
ment effects,
80 which do seem to be sustained,with symp-
tomatic deterioration (sometimes rapid) when treatment
is withdrawn.
81
Conclusion
As our understanding of the pathological processes
underpinning neurodegenerative disorders becomes
greater, we might hope that clinical classification and
detection of subtypes would become more precise.The
example of DLB suggests that this may not be so
straightforward.The majority of cases of dementia in
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Figure 2. Cholinesterase inhibitors in dementia with Lewy bodies (DLB).
Twelve Alzheimer’s disease (AD) patients and four DLB
patients were treated with donepezil 5 mg/day for 6 months.
Nonsignificant difference in changes on BEHAVE-AD
(Behavioral Pathology in Alzheimer’s Disease Rating Scale).
MMSE, Mini-Mental State Examination.
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eolder people appear to be related to multiple and over-
lapping pathologies and this is reflected in considerable
clinical heterogeneity.Clinical syndromes such as “prob-
able”DLB or AD are useful predictors of the predom-
inant underlying disease process and are of particular
use in planning treatment approaches.The new chal-
lenge is to devise better methods of determining the
atypical and mixed pathology cases with greater accu-
racy, acknowledging the existence of clinical and bio-
logical overlap.
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Demencia con cuerpos de Lewy
La demencia con cuerpos de Lewy (DCL) es la
segunda causa más común de demencia neurode-
generativa en las personas de edad avanzada y
representa el 10% a 15% de todos los casos. Ocupa
parte de un espectro que incluye la enfermedad de
Parkinson y la insuficiencia autonómica primaria.
Todas estas enfermedades comparten una patolo-
gía neural que se basa en una agregación anormal
de la proteína sináptica  -sinucleína. Es importante
identificar pacientes con DCL con precisión ya que
ellos tienen síntomas específicos, deterioros y dis-
capacidades funcionales que difieren de otros sín-
dromes comunes de demencia como la enfermedad
de Alzheimer, el deterioro cognitivo vascular y la
demencia frontotemporal. Se han validado criterios
diagnósticos clínicos para la DCL mediante la autop-
sia, pero fallan en la detección de una minoría no
despreciable de casos con presentaciones atípicas
que a menudo se deben a la presencia de patología
mixta. Los pacientes con DCL tienen frecuente-
mente graves reacciones de sensibilidad a los neu-
rolépticos, las que están asociadas con un aumento
significativo de la morbilidad y de la mortalidad. El
tratamiento con inhibidores de la colinesterasa en
general es bien tolerado y mejora significativa-
mente los síntomas cognitivos y neuropsiquiátricos.
Aunque virtualmente la DCL no se reconocía hace
20 años, dentro de esta década podría llegar a ser
uno de los trastornos neurodegenerativos más tra-
tables de la vejez.
La démence à corps de Lewy
La démence à corps de Lewy (DCL) représente la deu-
xième cause la plus fréquente des démences neuro-
dégénératives chez les sujets âgés, soit 10 à 15 % de
l’ensemble des cas. Elle appartient à un éventail qui
va de la maladie de Parkinson à la déficience auto-
nome primaire. Toutes ces maladies partagent une
pathologie neuronale basée sur une agrégation
anormale de la protéine synaptique  -synucléine. Il
est important d’identifier avec précision les patients
atteints de DCL car leurs symptômes, déficits ou inca-
pacités fonctionnelles sont spécifiques et diffèrent
des autres syndromes démentiels courants comme la
maladie d’Alzheimer, le déficit vasculaire cognitif et
la démence frontotemporale. Les critères diagnosti-
ques cliniques pour la DCL ont été validés par autop-
sie mais une minorité non négligeable n’est pas
détectée, il s’agit de cas atypiques dont la patholo-
gie est souvent mixte. Les patients atteints de DCL
ont souvent une hypersensibilité sévère aux neuro-
leptiques, associée à une morbidité et une mortalité
significativement accrues. Le traitement par anti-
cholinestérasiques est habituellement bien toléré et
améliore considérablement les symptômes cognitifs
et neuropsychiatriques. Bien que pratiquement
méconnue il y a 20 ans, la DCL pourrait devenir au
cours des 10 ans à venir l’une des maladies neurodé-
génératives de survenue tardive les plus accessibles
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